BioInvent International AB (publ) (LON:0H22)

Market Cap	160.56M +2.8%
Revenue (ttm)	17.34M +258.3%
Net Income	-26.69M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,874
Open	29.35
Previous Close	30.60
Day's Range	29.75 - 29.75
52-Week Range	19.46 - 40.45
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About LON:0H22

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat solid tumors; BI-1910, an anti-TNFR2 antibod...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 112
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H22

Financial Performance

In 2025, LON:0H22's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.

Financial numbers in SEK